The premature demise of this mechanism has meant that, in relation to a costly health resource, we are unaware of the number of children treated with growth hormone, whether there are selection differences between major centres, whether children are treated early enough and with appropriate doses and frequency of injections, and whether they respond adequately.
The Kabi Pharmacia International Growth Study (KIGS), an international postmarketing safety and efficacy study, provides growth hormone prescribing centres with the opportunity to review their own practice by comparison with national and international standards. The current KIGS database holds anonymised data on over 10 000 children of whom more than 1300 have been enrolled in the UK since 1988. Thus 30-40% of all children receiving growth hormone in the UK are entered into KIGS.
In this paper the KIGS database has been used to compare practice in the UK with that in other European countries, to compare clinics within the UK, and to identify criteria that could be used in audit. Recommended criteria for the diagnosis of IGHD included two standard provocation tests giving growth hormone concentrations in serum or plasma less than 10 ,ug/l (20 mU/l). Criteria for idiopathic short stature (not a licenced indication in the UK) included normal birth weight, normal body proportions, absence of chronic organic, psychiatric or emotional disorder, normal nutrition, and a growth hormone concentration in serum or plasma ¢'10 ,ug/l (:20 mU/l).
Data from growth hormone treated patients were entered into the main database, preserving both anonymity of patients and confidentiality of information for each clinic and country. COUNTRIES Similarly first year height velocity in prepubertal girls with Turner's syndrome is predicted by the same factors (except for birth weight SD score) but with a different order of relative importance and weighting; height velocity (cm/year)=2-02-0-19 (age) +0-28 (weekly frequency of injections) +1 -92 (dose of growth hormone IU/kg/week)+0 37 (target height SD score-height SD score) +0-028 (weight for height index) (R2=0-25; error SD= 1 52). A significantly lower observed response than predicted would imply the presence of other adverse factors.
The difference between observed and predicted height velocities in the first year of growth hormone treatment has been expressed as SD score; the expectation is that the mean . . . . . . . . . . . . --* -. . . . . . . #  . . . . . . . . . . . . . . . . . . . . . . . Figure 3 Observed v predicted growth velocity in the first year ofgrowth hormone treatment expressed as SD score, or 'responsiveness' to growth hormone, of children with IGHD for different UK clinic populations, with mean values (bars).
Price, J7ohnston, Betts, Buckler, Donaldson on behalf of the participants of the Kabi Pharmacia International Growth Study in the UK hormone treated patients from different clinics and from the UK as a whole. As such a significant proportion of all growth hormone treated patients in the UK (30-40%) has been enrolled it becomes likely that this group is representative of the whole. Furthermore it is possible to compare clinic populations that have complete enrolment. Assuming that the description of clinical practice is representative of the UK, a number of potential audit criteria are proposed.
The first criterion proposed is that of prevalence of growth hormone treated IGHD children, based on the premises that the real prevalence of IGHD is likely to be similar between regions and countries and that the need for treatment is the same. The prevalence within an auditable UK region was 27 per million and within the UK (as a whole) 18-24 per million. These prevalences are a third to a half of that seen in Sweden and might suggest that ascertainment within the UK is very incomplete. The prevalences of girls treated for Turner's syndrome, however, are very similar between the auditable UK region and Sweden. In order to achieve sufficiently early diagnosis of short stature due to pathological causes, the authors consider that increased prominence should be given to the inclusion of height measurements in the health assessment of young children. Measurement of height is non-invasive and remains quite fundamental to understanding health and disease in a child and in a community.
We have suggested a number of audit criteria applicable to treatment with biosynthetic growth hormone based on our interpretation of analysis of clinical practice in several UK clinics and European countries (table 5) .
Audit criteria and standards are not synonymous with optimal or ideal clinical practice and there will doubtless be considerable discussion about their appropriateness. However, it is our contention that this is an area that requires audit and KIGS with its unrivalled patient numbers has the potential for generating valuable information on efficacy and safety of growth hormone. In addition, enrolment of children into KIGS requires the clinician to keep regular and accurate documentation of growth and pubertal development in a format that can be shared with colleagues, a discipline that facilitates audit of a powerful and costly treatment.
